CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice

Blood
Maria Paola MartelliBrunangelo Falini

Abstract

Acute myeloid leukemia (AML) with mutated NPM1 shows distinctive biologic and clinical features, including absent/low CD34 expression, the significance of which remains unclear. Therefore, we analyzed CD34(+) cells from 41 NPM1-mutated AML. At flow cytometry, 31 of 41 samples contained less than 10% cells showing low intensity CD34 positivity and variable expression of CD38. Mutational analysis and/or Western blotting of purified CD34(+) cells from 17 patients revealed NPM1-mutated gene and/or protein in all. Immunohistochemistry of trephine bone marrow biopsies and/or flow cytometry proved CD34(+) leukemia cells from NPM1-mutated AML had aberrant nucleophosmin expression in cytoplasm. NPM1-mutated gene and/or protein was also confirmed in a CD34(+) subfraction exhibiting the phenotype (CD34(+)/CD38(-)/CD123(+)/CD33(+)/CD90(-)) of leukemic stem cells. When transplanted into immunocompromised mice, CD34(+) cells generated a leukemia recapitulating, both morphologically and immunohistochemically (aberrant cytoplasmic nucleophosmin, CD34 negativity), the original patient's disease. These results indicate that the CD34(+) fraction in NPM1-mutated AML belongs to the leukemic clone and contains NPM1-mutated cells exhibiting propertie...Continue Reading

References

Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M C MagliE Boncinelli
Aug 30, 2002·Leukemia·M EngelhardtY Guo
Sep 21, 2004·Oncogene·Jennifer K WarnerJohn E Dick
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Apr 11, 2006·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·David R ParksWayne A Moore
Jul 25, 2006·Nature·Andrei V KrivtsovScott A Armstrong
Dec 22, 2006·European Journal of Clinical Investigation·A W HauswirthP Valent
Oct 24, 2007·Nature Biotechnology·Fumihiko IshikawaLeonard D Shultz
Feb 12, 2008·Oncogene·E McCormackB T Gjertsen
Mar 1, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonBrunangelo Falini
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Oct 22, 2008·Cell Stem Cell·Tsvee LapidotOrit Kollet
Nov 7, 2008·Nature·Timothy J LeyRichard K Wilson
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Sep 23, 2009·Current Opinion in Oncology·Brunangelo FaliniMaria Paola Martelli

❮ Previous
Next ❯

Citations

Nov 26, 2010·Annals of Hematology·Ugo Testa
Sep 21, 2013·International Journal of Hematology·Yoshikane Kikushige, Toshihiro Miyamoto
Nov 23, 2012·Pharmacogenomics·Soizic GuihardMeyling H Cheok
Jul 9, 2013·Oncogene·D H WisemanT C P Somervaille
Mar 14, 2013·Biochimica Et Biophysica Acta·Natasha S BartenevaIvan A Vorobjev
Oct 15, 2014·Seminars in Hematology·Ashley M Perry, Eyal C Attar
Jul 5, 2011·Blood Reviews·Brunangelo FaliniMaria Paola Martelli
Dec 15, 2015·Annals of the New York Academy of Sciences·Aditi VediElisa Laurenti
Nov 23, 2015·Best Practice & Research. Clinical Haematology·Brunangelo Falini, Maria Paola Martelli
Feb 26, 2013·Protein Science : a Publication of the Protein Society·Luca Federici, Brunangelo Falini
Jan 3, 2013·Cytometry. Part B, Clinical Cytometry·Daniela S KrauseFrederic I Preffer
Aug 21, 2012·Annals of the New York Academy of Sciences·Yoshikane Kikushige, Koichi Akashi
Jun 25, 2015·British Journal of Haematology·Wendelien ZeijlemakerGerrit J Schuurhuis
Apr 22, 2015·British Journal of Haematology·Brunangelo FaliniMaria Paola Martelli
Nov 30, 2010·Cell Stem Cell·Yoshikane KikushigeKoichi Akashi
Dec 25, 2012·Blood Reviews·Maria Paola MartelliBrunangelo Falini
Feb 26, 2013·Blood·Paolo SportolettiBrunangelo Falini
Oct 30, 2010·Blood·Brunangelo FaliniTorsten Haferlach
May 7, 2016·Blood·Kapil N Bhalla, Warren Fiskus
Sep 15, 2016·Expert Opinion on Drug Discovery·Angelo B A Laranjeira, Sherry X Yang
Feb 6, 2017·Blood·Daniel Thomas, Ravindra Majeti
Feb 3, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mandeep KaurJianzhu Chen
Oct 3, 2019·Leukemia·Melanie KahlTino Schenk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.